Tenaya Therapeutics TNYA Stock
Tenaya Therapeutics Price Chart
Tenaya Therapeutics TNYA Financial and Trading Overview
| Tenaya Therapeutics stock price | 4.46 USD |
| Previous Close | 6.9 USD |
| Open | 6.85 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 1000 |
| Day's Range | 6.48 - 6.85 USD |
| 52 Week Range | 1.64 - 8.09 USD |
| Volume | 320.86K USD |
| Avg. Volume | 666.22K USD |
| Market Cap | 448.03M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.68 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.33 USD |
TNYA Valuation Measures
| Enterprise Value | 327.71M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.3333333 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.0794537 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.718 |
Trading Information
Tenaya Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 23.61% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.09 USD |
| 52 Week Low | 1.64 USD |
| 50-Day Moving Average | 5.9 USD |
| 200-Day Moving Average | 3.59 USD |
TNYA Share Statistics
| Avg. Volume (3 month) | 666.22K USD |
| Avg. Daily Volume (10-Days) | 404.82K USD |
| Shares Outstanding | 66.87M |
| Float | 41.66M |
| Short Ratio | 2.75 |
| % Held by Insiders | 4.06% |
| % Held by Institutions | 87.81% |
| Shares Short | 2.45M |
| Short % of Float | 5.41% |
| Short % of Shares Outstanding | 3.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.41% |
| Return on Equity (ttm) | -53.53% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -120559000 USD |
| Net Income Avi to Common (ttm) | -124346000 USD |
| Diluted EPS (ttm) | -2.42 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 147.81M USD |
| Total Cash Per Share (mrq) | 2.21 USD |
| Total Debt (mrq) | 14.12M USD |
| Total Debt/Equity (mrq) | 6.56 USD |
| Current Ratio (mrq) | 8.01 |
| Book Value Per Share (mrq) | 3.222 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -105958000 USD |
| Levered Free Cash Flow (ttm) | -77196752 USD |
Profile of Tenaya Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 171 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 825 6900 |
| Website | https://www.tenayatherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 141 |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Q&A For Tenaya Therapeutics Stock
What is a current TNYA stock price?
Tenaya Therapeutics TNYA stock price today per share is 4.46 USD.
How to purchase Tenaya Therapeutics stock?
You can buy TNYA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tenaya Therapeutics?
The stock symbol or ticker of Tenaya Therapeutics is TNYA.
Which industry does the Tenaya Therapeutics company belong to?
The Tenaya Therapeutics industry is Biotechnology.
How many shares does Tenaya Therapeutics have in circulation?
The max supply of Tenaya Therapeutics shares is 78.52M.
What is Tenaya Therapeutics Price to Earnings Ratio (PE Ratio)?
Tenaya Therapeutics PE Ratio is now.
What was Tenaya Therapeutics earnings per share over the trailing 12 months (TTM)?
Tenaya Therapeutics EPS is -1.68 USD over the trailing 12 months.
Which sector does the Tenaya Therapeutics company belong to?
The Tenaya Therapeutics sector is Healthcare.
Tenaya Therapeutics TNYA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}